Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX ® Breast Recurrence Score Assay

Curtit, Elsa; Mansi, Laura; Maisonnette-Escot, Y.; Sautière, J.-L.; Pivot, Xavier

doi:10.1016/j.ejso.2016.11.016

Cited by 24 publications

(20 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One such limitation is that the cutoff for gene panels varies between studies. The consistent findings of large prospective clinical trials further validate the clinical utility of the RS and strongly suggest that adjuvant chemotherapy may be spared for patients with very low (< 10) RS results [ 37 ]. We are seeking consensus on the evidence and opinions regarding correct cutoff points and how to deal with patients of intermediate risk identified by the RS.…”

Section: Limitation Of Multigene Panelsmentioning

confidence: 78%

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint

Xin

Liu

Martin³

et al. 2017

World J Oncol

View full text Add to dashboard Cite

The AJCC Cancer Staging Manual, eighth edition published in late 2016, will become the new global guideline for cancer diagnosis and treatment from January 1, 2018. The new edition for the tumor staging system has numerous updates, including building up the prognostic stage group of tumors for the first time and adding a large number of non-anatomical factors into the prognostic evaluation. Oncotype DX and MammaPrint are two of the genomic predictors that will be part of routine clinical practice in the future. Numerous studies have proved the clinical utility of multigene panels in predicting clinical outcome and treatment response. Here we present our review of the studies on these multigene panels and their application to breast cancer.

show abstract

Section: Limitation Of Multigene Panelsmentioning

confidence: 78%

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint

Xin

Liu

Martin³

et al. 2017

World J Oncol

View full text Add to dashboard Cite

show abstract

“…With regard to this aim, gene expression signatures assessed on tumor tissue, such as the 21-gene recurrence score assay Oncotype DX®, Mammaprint®, EndoPredict® or PAM50®, are of interest. They estimate the risk of distant recurrence and Oncotype DX® also predicts the magnitude of benefit of adjuvant chemotherapy for patients with early-stage breast cancer [ 45 – 49 ]. Genes involved in this signature are different from those used in the 94-SNP score.…”

Section: Discussionmentioning

confidence: 99%

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

et al. 2017

View full text Add to dashboard Cite

BackgroundGenome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combined effect of the 94 risk alleles can be calculated to measure the global risk of breast cancer. We aimed to test the hypothesis that the 94-SNP-based risk score is associated with clinico-pathological characteristics, breast cancer subtypes and outcomes in early breast cancer.MethodsA 94-SNP risk score was calculated in 8703 patients in the PHARE and SIGNAL prospective case cohorts. This score is the total number of inherited risk alleles based on 94 selected SNPs. Clinical data and outcomes were prospectively registered. Genotyping was obtained from a GWAS.ResultsThe median 94-SNP risk score in 8703 patients with early breast cancer was 77.5 (range: 58.1–97.6). The risk score was not associated with usual prognostic and predictive factors (age; tumor, node, metastasis (TNM) status; Scarff-Bloom-Richardson grade; inflammatory features; estrogen receptor status; progesterone receptor status; human epidermal growth factor receptor 2 (HER2) status) and did not correlate with breast cancer subtypes. The 94-SNP risk score did not predict outcomes represented by overall survival or disease-free survival.ConclusionsIn a prospective case cohort of 8703 patients, a risk score based on 94 SNPs was not associated with breast cancer characteristics, cancer subtypes, or patients’ outcomes. If we hypothesize that prognosis and subtypes of breast cancer are determined by constitutional genetic factors, our results suggest that a score based on breast cancer risk-associated SNPs is not associated with prognosis.Trial registrationPHARE cohort: NCT00381901, Sept. 26, 2006 – SIGNAL cohort: INCa RECF1098, Jan. 28, 2009Electronic supplementary materialThe online version of this article (doi:10.1186/s13058-017-0888-4) contains supplementary material, which is available to authorized users.

show abstract

“…Finding predictive factors that are associated with response or failure to a treatment and thus help to identify the most effective therapy remains the ultimate challenge to provide patients with personalized medicine. With regard to this aim, gene expression signatures [45][46][47][48][49]. Genes involved in this signature are different from those used in the 94-SNP score.…”

Section: Discussionmentioning

confidence: 99%

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

et al. 2016

Self Cite

View full text Add to dashboard Cite

Background: Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combined effect of the 94 risk alleles can be calculated to measure the global risk of breast cancer. We aimed to test the hypothesis that the 94-SNP-based risk score is associated with clinico-pathological characteristics, breast cancer subtypes and outcomes in early breast cancer.

show abstract

Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX ® Breast Recurrence Score Assay

Cited by 24 publications

References 63 publications

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

Contact Info

Product

Resources

About